Disclosure of interest: Laurine Bedoucha : nothing to disclose Claire Gobron : nothing to disclose Fabrice Vallee : nothing to disclose Etienne Gayat : nothing to disclose Peggy Reiner : nothing to disclose Candice Sabben : nothing to disclose Michael Obadia : nothing to disclose Perrine Boursin : nothing to disclose Estelle Dubus : nothing to disclose Eric Jouvent : nothing to disclose Mikael Mazighi : nothing to disclose Lucas Di Meglio : nothing to disclose Poster Session I - ACUTE ISCHEMIC STROKE MANAGEMENT 01.00 - ACUTE ISCHEMIC STROKE MANAGEMENT - 01.01 - ACUTE MANAGEMENT - Neither thrombolysis nor thrombectomy P037 - ESOC25-504 CLINICAL AND ORGANISATIONAL PRACTICES IN THE ACUTE PHASE OF ISCHAEMIC STROKE IN QUEBEC BY SEX AND AGE: RESULTS OF A DESCRIPTIVE STUDY Amlie Blanger 1 , Julie Houle 1 , Line Beaudet 2 1 Universit du Qubec Trois-Rivires, Trois-Rivires, Canada, 2 Centre de recherche du Centre hospitalier de l'Universit de Montral (CRCHUM), Montral, Canada Background and Aims: The quality of interdisciplinary care during the acute phase of ischaemic stroke remains underexplored in Canada, particularly in Quebec
Dean M, Austin J, Jinhong R, Johnson ME, Lantvit DD, Burdette JE (2018) The flavonoid apigenin is a progesterone receptor modulator with in vivo activity in the uterus
These actions modulate NMDA and AMPA receptor activity, ensuring a balanced excitatory-inhibitory environment
The E2E1-NP design is generalizable across HCV genotypes Next, we wanted to explore the applicability of the E2E1-I53-50A design for producing nanoparticle immunogens based on a different genotype
